

FOI 23/866

Dear,

Thank you for your request of 08 November 2023. You requested:

I was just wondering if there is any update as to when the cystic fibrosis medication would be licensed in the uk for 2 years and above?

We have recently published information on our website which confirms extensions to the licenses of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old, on 15 November 2023. Please see the link below for further information:

[Cystic fibrosis drugs Kaftrio and Kalydeco licensed for patients aged two to five years old - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/news/cystic-fibrosis-drugs-kaftrio-and-kalydeco-licensed-for-patients-aged-two-to-five-years-old)

If you need any further information, or if the above is not what your email was referring to, then please come back to us.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Or online via: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/>

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU